OTCQB - ADMT

1

Forward-Looking Statements

This presentation contains “forward-looking statements” which are subjectto risks and uncertainties and management may make additional forward-looking statements in response to questions. Forward-looking statementsare made pursuant to the Safe Harbor provisions of the Private SecuritiesLitigation Reform Act of 1995. Forward-looking statements includestatements with respect to the Company’s beliefs, plans, objectives, goals,expectations, anticipations, assumptions, estimates, intentions, and futureperformance and involve known and unknown risks, uncertainties and otherfactors, which may be beyond the Company’s control, and which may causethe Company’s actual results, performance or achievements expressed orimplied by such forward-looking statements to differ materially from suchforward-looking statements. All statements, other than statements ofhistorical fact, are statements that could be forward-looking statements.These forward-looking statements may not be realized due to a variety offactors, including, without limitation: the factors listed under “Risk Factors”in the Company’s annual report on Form 10-KSB for the fiscal year endedMarch 31, 2015. The Company assumes no obligation to update theinformation contained in this presentation.

2

3

ADMT - a diversified, technology-baseddeveloper and manufacturer of innovativetechnologies and products in two distinctindustry segments:

- electronic medical devices- eco-friendly chemicals

4

ADMT Core Competency:

The ability to conceptualize a technology, bring it through design, development, regulatory requirements, into manufacturing and commercialization - all in-house.

Assembled proficient, experienced multi-disciplinary team of engineers and technologists for development of proprietary products.

5

Pivotal change in 2013

ACA Effect on Medical Device Industry

ADMT Shifts Strategy Offer Contract Engineering Services to Outsourcers as Catalyst for “SEG”

Design, Development, Regulatory, 3D Prototyping, Clinical Study Support, Manufacturing

ConceptToQuantity.com

6

Engineering Services as Catalyst

Selective - Accept clients that lead to ongoing manufacturing revenues

Expand relationships for partnership opportunities

Generate cash flow to internally fund proprietary technologies

7

Results of SEG in First Year

Fiscal Year End March 31, 2015 - Turnaround

Return To Profitability Revenue increase of 58% Positive Cash Flow From

OperationsFYE 3/31/15 FYE 3/31/14 FYE 3/31/13

Net Revenues $2,850,548 $1,809,623 $1,580,841Cost of Sales $1,485,590 $1,053,930 $ 782,648Gross Profit $1,364,958 $ 755,693 $ 798,193Operating Expenses $1,115,009 $ 979,485$1,336,473Income (loss) from operations $ 249,949 $( 223,792) $( 538,280)Total other income $ 108,841 $( 1,422) $ 1,150Net income (loss) $ 358,790 $( 225,214) $( 537,130)Net income (loss)/share $0.01 $(0.00) $(0.01)

8

Key DevelopmentsSep 9, 2014 Expanded Internal CapabilitiesSep 18, 2014 Added Advisory Board MemberSep 29, 2014 Join TrioTech ConsortiumOct 21, 2014 V. Grasso, MD Joins as CMIOApr 21, 2015 Second ExpansionJun 23, 2015 Contract for Med-Sim Manikin

9

Selective - Accept clients that lead to ongoing manufacturing revenues

- Major client with multiple projects

- Several clients with single projects

Continued referrals for additional clients from satisfied client base.

10

Expand relationships for partnership opportunities

- Harvard Researcher Dr. DeNovi- TrioTech Venture Projects- International Clients to US

Market

Strategic relationships utilizing ADMT Infrastructure

11

Generate cash flow to internally fund proprietary technologies

Sonotron® - non-invasive device, for treatment of inflammatory joint pain Aurex-3® FDA-cleared device for treatment and control of tinnitus NCCDtm Neuro-Cerebral Coronal Discharge

for treatment of neuro-conditions

Additional medical electronic devices in pipeline

12

Continued Revenues from Eco-Friendly Products Cost competitive replacements for hazardous

industrial chemicals

Coatings, adhesives, resins, primers additives and antistatic products

Used in food, cosmetic, drug packaging, construction, home improvement industries and electronics.

13

ADMT - InfrastructureExperienced, multi-disciplinary, in-house team of med-dev engineers and technologistsVeteran product development & mfg personnelCost effective and efficient operationsIncubates new product design and usesDesign, development,regulatory, rapid 3-D prototyping & manufacturing

14

ADM Tronics Infrastructure (cont.)

Positive industry reputationFDA-Registered Manufacturing Facility

US & international regulatory services:

GMP/QSR/CE/CMDCAS documentation,

FDA apps - IDE, 510(k), clinical study support, etc.

15

Future Prospects

Continued Growth of Engineering Services

Manufacturing Revenue Growth From Clients

Strategic Relationship Expansion

Potential FDA-Clearance of Sonotron

16

Equity Information:Listing: OTCQB: ADMT

Recent share price: $0.1952 week range: $0.06 - $0.2530-Day Avg. Daily Volume: 18,000Shares outstanding: 64.9 millionMarket capitalization: $12 million

17

Thanks!OTCQB: ADMT

ADM Tronics Unlimited, Inc.224S Pegasus Avenue, Northvale, NJ 07647 USAadmtronics.com concepttoquantity.com